Novartis says the acquisition of Massachusetts-based biotech firm CoStim will accelerate its cancer immunotherapy programme but will not add any new technology.
Outdated technology is one of the greatest challenges in creating next-generation biodrugs, says Jonathan Robinson, who is leading the development of a £38m ($63m) national biomanufacturing hub in the UK.
